Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
Paul H Naylor , Milton Mutchnick Department of Internal Medicine/Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA Abstract: African Americans (AA) in the US are twice as likely to be infected with hepatitis C virus (HCV) compared to the non-Hispanic-white US pop...
Guardado en:
Autores principales: | Naylor PH, Mutchnick M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e33799ff9bff4dcf848c544283271e16 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram V, et al.
Publicado: (2016) -
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol S, et al.
Publicado: (2016) -
Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014) -
Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein D, et al.
Publicado: (2019) -
Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics
por: Magda Shaheen, et al.
Publicado: (2021)